Publicacións en colaboración con investigadores/as de Uppsala University Hospital (4)

2019

  1. Author Correction: ‘Stealth’ corporate innovation: an emerging threat for therapeutic drug development (Nature Immunology, (2019), 20, 11, (1409-1413), 10.1038/s41590-019-0503-1)

    Nature Immunology

  2. ‘Stealth’ corporate innovation: an emerging threat for therapeutic drug development

    Nature Immunology

2014

  1. Updated results from OCTAVIA (front-line bevacizumab, carboplatin and weekly paclitaxel therapy for ovarian cancer)

    European Journal of Cancer

2013

  1. Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer

    European Journal of Cancer, Vol. 49, Núm. 18, pp. 3831-3838